Seizure control by decanoic acid through direct AMPA receptor inhibition

Pishan Chang,1 Katrin Augustin,1 Kim Boddum,2 Sophie Williams,2 Min Sun,2 John A. Terschak,3 Jörg D. Hardege,3 Philip E. Chen,1,* Matthew C. Walker2,* and Robin S. B. Williams1,*

See Rogawski (doi:10.1093/awv369) for a scientific commentary on this article.

*These authors contributed equally to this work.

The medium chain triglyceride ketogenic diet is an established treatment for drug-resistant epilepsy that increases plasma levels of decanoic acid and ketones. Recently, decanoic acid has been shown to provide seizure control \emph{in vivo}, yet its mechanism of action remains unclear. Here we show that decanoic acid, but not the ketones \(\beta\)-hydroxybutyrate or acetone, shows antiseizure activity in two acute \emph{ex vivo} rat hippocampal slice models of epileptiform activity. To search for a mechanism of decanoic acid, we show it has a strong inhibitory effect on excitatory, but not inhibitory, neurotransmission in hippocampal slices. Using heterologous expression of excitatory ionotropic glutamate receptor AMPA subunits in \textit{Xenopus} oocytes, we show that this effect is through direct AMPA receptor inhibition, a target shared by a recently introduced epilepsy treatment perampanel. Decanoic acid acts as a non-competitive antagonist at therapeutically relevant concentrations, in a voltage- and subunit-dependent manner, and this is sufficient to explain its antiseizure effects. This inhibitory effect is likely to be caused by binding to sites on the M3 helix of the AMPA-GluA2 transmembrane domain; independent from the binding site of perampanel. Together our results indicate that the direct inhibition of excitatory neurotransmission by decanoic acid in the brain contributes to the anti-convulsant effect of the medium chain triglyceride ketogenic diet.

1 Centre for Biomedical Sciences, School of Biological Sciences, Royal Holloway University of London, Egham, TW20 0EX, UK
2 Department of Clinical and Experimental Epilepsy, Institute of Neurology, University College London, WC1N 3BG, UK
3 School of Biological, Biomedical and Environmental Sciences, University of Hull, Cottingham Road, Hull HU6 7RX, UK

Correspondence to: Prof. Matthew C Walker,
Department of Clinical and Experimental Epilepsy,
Institute of Neurology,
University College London,
WC1N 3BG, UK
E-mail: m.walker@ucl.ac.uk

Correspondence may also be addressed to: Prof. Robin S. B. Williams,
Centre for Biomedical Sciences,
School of Biological Sciences,
Royal Holloway University of London, Egham,
TW20 0EX, UK
E-mail: robin.williams@rhul.ac.uk

\textbf{Keywords:} AMPA receptors; decanoic acid; epilepsy; ketogenic diet; seizure control

\textbf{Abbreviations:} AMPA = \(\alpha\)-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; EPSC = excitatory postsynaptic current; Glu = ionotropic glutamate (AMPA) receptors; IPSC = inhibitory postsynaptic current; MCT = medium chain triglyceride; NMDA = N-methyl D-aspartic acid
Introduction

The medium chain triglyceride (MCT) ketogenic diet was first identified as a treatment for refractory epilepsy in 1971 (Huttenlocher et al., 1971). It has provided one of the most effective therapeutic approaches for children with drug-resistant epilepsy (Liu, 2008; Neal and Cross, 2010; Levy et al., 2012) and has recently been demonstrated to be effective in childhood epilepsy in a randomized control trial (Neal et al., 2009). However, the diet has adverse gastro-intestinal related side effects, such as diarrhoea, vomiting, bloating, and cramps (Liu, 2008). Furthermore, it has also been shown that there is a high attrition rate for the diet, due to many patients finding the diet difficult to tolerate (Levy et al., 2012). An understanding of the mechanism of action of the diet will not only provide insight into mechanisms underlying epilepsy, but also facilitate the development of novel drugs and better targeted dietary therapies that are effective in drug-resistant epilepsy, yet lack many of the adverse effects of the conventional MCT diet.

Understanding the therapeutic mechanism of the diet has been challenging (Rho and Sankar, 2008; Rho and Stafstrom, 2011). It was initially assumed that ketone production was the key to the diet’s antiepileptic effect, but there is a poor correlation between serum ketones and seizure control (Likhodi et al., 2000; Thavendiranathan et al., 2000). Moreover, in vitro and in vivo studies of the anticonvulsant effects of ketones have proved inconclusive (Likhodi et al., 2000; Thavendiranathan et al., 2000). In addition to ketones, the diet also causes an increase in plasma levels of the two fatty acids provided in MCT oil, the straight chain, 10-carbon decanoic acid, and the eight-carbon octanoic acid (Haidukewych et al., 1982; Sills et al., 1986a). Recently, it has been established that decanoic acid has antiseizure effects at clinically relevant concentrations in vitro and in vivo (Chang et al., 2013; Wlaz et al., 2015) but octanoic acid does not, and with previous in vivo pharmacokinetic data indicating that decanoic acid penetrates the blood–brain barrier (Oldendorf, 1973), these data suggest that decanoic acid directly contributes to the therapeutic effect of the MCT ketogenic diet. Indeed, in vitro, decanoic acid is more potent than valproic acid [a branched chain fatty acid isomer of octanoic acid, that is commonly used in the treatment of epilepsy (Chang et al., 2013), and which has been shown to act on phosphoinositide signalling in seizure control (Xu et al., 2007; Chang et al., 2012, 2014a)]. Thus, it is unclear if ketones or decanoic acid provide direct, acute antiseizure effects during administration of an MCT diet, and by what mechanism. These questions are addressed here.

Materials and methods

Animals

Male Sprague-Dawley rats were housed in cages under controlled environmental conditions (24–25°C; 50–60% humidity; 12-h light/dark cycle) with free access to food and water. All efforts were made to minimize the number of animals used. All experiments were performed under personal and project licenses approved by the Home Office, London, UK under regulations of the UK Animal (Scientific Procedures) Act, 1986.

Slice preparation

Male Sprague-Dawley rats (postnatal Days 19–30) were sacrificed using an overdose of isoflurane or pentobarbitone (500 mg/kg). After decapitation the brain was rapidly removed, the hippocampus or entorhinal cortex-hippocampus slices were dissected from the brain and 350-µM thick transverse slices were prepared on a VT1200S vibratome (Leica) or Vibratome (Vibratome® 1500 sectioning system, Instracell). The slicing was performed in ice-cold sucrose-based solution containing (in mM): 75 sucrose, 87 NaCl, 22 glucose, 2.5 KCl, 7 MgCl2, 1.25 NaH2PO4, 0.5 CaCl2 and 25 NaHCO3, pH 7.4, 315–330 mOsm equilibrated with 95% O2 plus 5% CO2. The slices were then stored in a continuously oxygenated humidified interface holding chamber containing oxygenated artificial CSF (in mM): 120 NaCl, 22 glucose, 2.5 KCl, 1.3 MgSO4, 1 NaH2PO4, 25 NaHCO3 and 2.5 CaCl2, pH 7.4 ± 0.2 mOsm, where they recovered for at least 1 h before use.

Electrophysiology

In vitro seizure model

During the experiment, slices were transferred from the interface chamber into a submerged recording chamber, designed to optimize wash-in and wash-out of drugs, and continuously perfused using gravity feed at 3–6 ml/min with prewarmed (36°C) oxygenated artificial CSF (95% O2, 5% CO2). Field potentials were recorded with a glass microelectrode (1–2 MΩ) filled with artificial CSF solution placed in stratum radiatum of CA1 and were filtered at 1 kHz and digitized at 2 kHz (using an npi EXT-02F extracellular amplifier recorded with WinEDR software). In the pentylentetrazol model, the epileptiform (paroxysmal) activity was induced by application of pentylentetrazol (2 mM) to the perfusate and [K+] was increased (to 6 mM); in low-Mg2+-model, the epileptiform activity was elicited by using Mg2+-free artificial CSF. Once the frequency of the paroxysmal activity was stable for at least 10 min, compounds were applied to the perfusate for the following 40 min, and washed out for a remaining 20 min. The anticonvulsant effects were evaluated by measuring the change in the frequency of the discharges at minute intervals. The discharge frequency was then averaged every 5 min during the experiment and normalized to baseline. The compounds applied in this study included: 1% dimethyl sulfoxide (DMSO), acetone (10 mM, Sigma), (±)-sodium 3-hydroxybutyrate (BHB) (10 mM, Sigma), and decanoic acid (1 mM, Alfa Aesar Pty). Acetone and decanoic acids were prepared as 1000 × stocks in DMSO, and BHB was prepared as 100 × stock. Stocks were dissolved in artificial CSF to achieve their final concentrations during experiments, and where applicable, experiments included constant levels of DMSO.

Whole-cell patch clamp

For electrophysiological recording, the slices were placed in a recording chamber constantly perfused with 32–34°C
oxygenated artificial CSF solution using a gravity-driven perfusion system. Whole-cell patch clamp recordings were performed on CA1 pyramidal cells (input resistance 330 ± 70 MΩ) visualized using an infrared differential contrast imaging system. For patching, standard walled borosilicate glass pipettes with a resistance of 2.5–3.5 MΩ were used, filled with an intracellular pipette solution containing (in mM): 120 Cs-methanesulphonate, 10 HEPES, 0.2 EGTA, 8 NaCl, 0.2 MgCl₂, 2 Mg-ATP, 0.3Na-GTP, 5 QX314-Br, 10 phosphocreatine, pH adjusted to 7.2 and osmolality adjusted to 296 mOsm. Series resistance was monitored throughout experiments using a −5 mV step command and cells showing a >20% change in series resistance, a series of resistance of >20 MΩ or an unstable holding current were rejected. Recordings of excitatory postsynaptic currents (EPSCs) were performed in the presence of DL-APV (DL-2-amino-5-phosphonopentanoic; 100 μM), picrotoxin (100 μM) and CGP55845 (5 μM) to block NMDA-, GABA₅- and GABA₆-receptors, respectively. Decanoic acid (Sigma) was added to the perfusion solution. EPSCs were evoked by stimulation of Schaffer collaterals. Paired pulses were evoked with stimulation separated by 50 ms. Inhibitory postsynaptic current (IPSCs) were recorded in the presence of DL-APV (100 μM), NBQX (10 μM) and CGP55845 (5 μM) to block NMDA-, AMPA- and GABA₆-receptors, respectively.

Recordings were obtained using a MultiClamp 700B amplifier (Axon instruments) and filtered at 4 kHz, digitized at 10 kHz, and stored on a PC. LabView8 (National instruments) was used for data acquisition and off-line analysis.

In vitro RNA transciption of AMPA receptor subunits

The AMPA receptor (flip isoform) cDNAs inserted in a SP6 polynmerase expression vector (pSP6T) were a generous gift from Prof. Ralf Schoepfer (NPP, UCL). RNA was transcribed in vitro from MluI linearized transcripts using the SP6 Promega RiboMAX® RNA synthesis kit according to manufacturer’s protocols except for the addition of 0.75 mM capping nucleotide m7G(5')ppp(5')G (Promega) and 1.6 mM GTP. cRNA concentrations and integrity were estimated by the intensity of fluorescence bands in RNA denaturating gels. AMPA receptor cRNAs were mixed in a nominal 1:1 ratio and ~5 ng was injected per oocyte.

Oocyte preparation and injection

Xenopus laevis oocytes were purchased from the European Xenopus Resource Centre, University of Portsmouth. Stage V to VI oocytes were mechanically dissected and then subjected to gentle shaking for ~30–50 min at room temperature with modified Barth’s solution (in mM): 88 NaCl, 1 KCl, 2.4 NaHCO₃, 0.82 MgCl₂, 0.77 CaCl₂, 15 Tris-Cl, adjusted to pH 7.4 with NaOH (Sigma-Aldrich), supplemented with 50 IU/ml penicillin and 50 μg/ml streptomycin (Invitrogen) and 50 μg/ml tetracycline (Sigma-Aldrich) and 1% collagenase (type 1A). Healthy oocytes were manually defolliculated and the injections of cRNA for homomeric subunits alone (GluA1), or heteromeric mixtures of two subunits together (GluA1/GluA2 or Glu2A/GluA3) were made using an automated Drummond Nanoinject II injector. The oocytes were then incubated at 17°C in modified Barth’s solution for at least 48 h before use in electrophysiological recordings.

Two-electrode voltage clamp recordings from oocytes

Experiments were performed at room temperature (~21–23°C). An oocyte was placed in a recording chamber (0.3–0.5 ml volume) and perfused with ND96 solution (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl₂, 1 mM MgCl₂, 5 mM HEPES, with pH adjusted to 7.5). Current and voltage electrodes were filled with 300 mM KCl and made from thin-walled borosilicate glass (GC150TF-7.5, Harvard Apparatus) using a PC-10 electrode puller (Narashige Instruments) and had resistances of 0.5–2 MΩ. Oocytes were voltage-clamped to a holding potential of −50 mV or −60 mV using a Turbo TEC-03 amplifier (npi electronics). Compounds were dissolved in distilled water or DMSO and dissolved in bathing solution to achieve their final concentrations during experiments, and were applied under gravity flow during the experiment by using a multi-valve perfusion system (VC3-8C, ALA Scientific Instruments). The bath solutions were perfused at a rate of 10 ml/min. Recordings were filtered at 20 Hz and digitized at 100 Hz (Digidata 1322A, Molecular Devices) before recording to computer hard disk. Data acquisition was performed using the Windows PC-based program, WinEDR v3.0.6 (John Dempster, University of Strathclyde, UK).

Molecular dynamics studies

SMILES format of each ligand was converted to 3D PDB files using Open Babel (Ver. 2.3.2). The obconformer function was then used to find the lowest energy conformation from 5000 test conformers after 100 geometry optimization steps. A GluA2 receptor molecule (Protein Data Bank Code 3KG2) downloaded from the Research Collaboratory for Structural Bioinformatics Protein Data Bank (RSCB PDB) was processed using AutoDock (Ver 1.5.6) in which solvent water molecules, duplicate subunits (B, C, and D), and bound ligands (zinc, β1.5.6) in which solvent water molecules, ZK1 [7-morpholin-4-yl-2,3-dioxo-6(trifluoromethyl)-3,4-dihydroquinoxalin-1(2H)-yl][methyl][phosphonic acid]) were removed. Polar hydrogens were retained after the addition of Kollman charges and the distribution of charge deficit. Beginning with the ligand in its lowest energy conformation, each was then allowed to rotate freely about its single bonds during the docking process. For 3KG2, the docking grid was set in a 126-unit box centred at x: 16.971, y: 40.698, and z: −106.466 with 0.528 Å spacing; this encompassed the entire transmembrane domain of the A subunit (Supplementary Fig. 6). The docking search parameters used AutoDock’s Genetic Algorithm with 25 runs of 2.5 million evaluations and an initial population size of 250. Upon completion of docking of each ligand, the numbers of conformations as well as the range of their binding energies were noted for each cluster of docking locations. The amino acid residues within 6 Å of the lowest energy conformation of each bound ligand were noted. The residues most frequently participating in binding with the various ligands were targeted as the most likely common binding site for 3KG2 (Supplementary Fig. 3).
**Statistical analysis**

The data from the electrophysiology experiments were analysed using GraphPad Prism software and SPSS (IBM) with IC50 values calculated using $y = 100 \div (1 + 10^{(x - \log IC50)})$. Statistical analysis was performed using ANOVA with Tukey post hoc test, paired t-test or unpaired t-test.

**Results**

**Decanoic acid, not ketones, acutely inhibits epileptiform activity**

We initially assessed whether the acute antiseizure effects of the MCT ketogenic diet are related to a direct effect of decanoic acid or ketone bodies (β-hydroxybutyrate and acetone). Here we used two different *in vitro* models of epileptiform activity generated by application of pentylenetetrazol (PTZ, 2 mM, K+ 6 mM), a model for generalized seizures, and following treatment, where (B) the frequency of epileptiform activity is plotted against time, following treatment, and also shown as a comparison of the mean (±SD) frequency of burst discharges averaged from 20 to 40 min post-compound addition. (C) Example trace recording of epileptiform activity (burst discharges) in hippocampal slices induced by low-Mg2+ conditions, as a model for drug-resistant seizures, and following treatment, where (D) the frequency of epileptiform activity is plotted against time, and also shown as a comparison of the mean (±SD) frequency of burst discharges averaged from 20 to 40 min post-compound addition. Significance indicated by ***P < 0.001 compared to control (ANOVA with Tukey post hoc test). All data were normalized to baseline. Data are provided from between n = 4 and 7 repeats.

**Decanoic acid acutely inhibits excitatory postsynaptic currents**

We next asked what the molecular mechanisms for the effect of decanoic acid in seizure control are likely to be. As most antiepileptic drugs modify synaptic transmission or neuronal excitability, we first tested the effect of decanoic acid on either excitatory or inhibitory neurotransmission by determining the effect of decanoic acid on evoked EPSCs and IPSCs in acute *ex vivo* hippocampal slices. For these experiments, we performed whole-cell patch clamp recordings from CA1 pyramidal neurons and stimulated the
stratum radiatum in the presence of NMDA-, GABA_A- and GABAB-receptor blockers to isolate AMPA receptor mediated EPSCs or in the presence of NMDA-, AMPA- and GABA_B-receptor blockers to isolate GABA_A receptor mediated IPSCs and applied 300 μM (52 μg/ml) decanoic acid [similar to peak serum concentration of children on the MCT diet (Sills et al., 1986a), and to the serum and brain concentrations necessary for acute seizure effects in mice (Wlaz et al., 2015)]. Decanoic acid decreased the EPSC amplitude by 38.9 ± 5.5%, (n = 6; P < 0.001; Fig. 2A and C), but had no significant effect on evoked IPSCs (Fig. 2B and D). Furthermore, decanoic acid (300 μM) had no effect on 1/CV² (CV, coefficient of variation) for EPSCs (decanoic acid versus baseline; n = 6: P = 0.95; Fig. 2E) or IPSCs (decanoic acid versus baseline; n = 6: P = 0.95; Fig. 2F), and did not affect the paired pulse ratio for EPSCs (decanoic acid versus baseline; n = 6; P = 0.69 Supplementary Fig. 1A and B), consistent with a postsynaptic locus of action. At a concentration comparable to the steady state of decanoic acid in children on the MCT diet (100 μM) (Sills et al., 1986a); decanoic acid still significantly reduced EPSC amplitudes by 17.0 ± 5.6% (P = 0.01; n = 6). Our results are, therefore, consistent with a significant (direct or indirect) effect of decanoic acid on postsynaptic excitatory (AMPA) receptor activity.

**Decanoic acid directly inhibits AMPA receptor activity**

To determine whether decanoic acid has a direct effect on AMPA receptor activity, we employed a heterologous
expression system in which AMPA receptor subunits (GluA2/3) were expressed in *Xenopus* oocytes and agonist elicited inward currents were used to test the inhibitory activity of decanoic acid. In these experiments, we measured the effect of decanoic acid, octanoic acid and valproic acid (all at 1 mM; \( n = 12 \)), on currents elicited by application of 100 \( \mu M \) L-glutamate. In line with its anticonvulsant efficacy (Chang et al., 2012, 2013), decanoic acid markedly reduced AMPA receptor currents (32.4 ± 2.0% of control, \( n = 24, P < 0.001; \) Fig. 3A and B), whereas octanoic acid had no effect. Valproic acid also showed no action on AMPA receptor currents. Inhibitory dose-response curves showed that the effect of decanoic acid was dose dependent (Fig. 3C and D), and more potent (mean IC50 = 0.52 ± 0.02 mM, \( n = 12 \) ) than that of octanoic acid (mean IC50 = 3.82 ± 0.03 mM, \( n = 10 \) ). The inhibition of glutamate elicited inward currents by decanoic acid was also seen in oocytes expressing GluA1 homomeric channels (Fig. 3E and F). Decanoic acid also inhibited AMPA receptors following activation with the selective high-affinity AMPA receptor agonist, AMPA (30 \( \mu M \); 16.7 ± 2.7% of AMPA alone; \( n = 8; P < 0.001 \) ) (Supplementary Fig. 2). This inhibitory effect indicates a direct, structurally specific inhibition of AMPA receptor currents by decanoic acid.

We next investigated if AMPA receptor inhibition could block epileptiform activity *in vitro* using the hippocampal/pentylenetetrazol seizure model. Here we tested whether GYKI 52466—a non-competitive AMPA receptor antagonist—at a concentration that gives the same degree of AMPA receptor antagonism as 1 mM decanoic acid (Arai, 2001).

---

**Figure 3** The direct effect of decanoic acid on AMPA receptor-mediated currents. In these experiments, *Xenopus* oocytes were used to express AMPA (GluA2/A3 or GluA1) receptors, and currents were measured following application of L-glutamate (100 \( \mu M \)) with membrane potential clamped to −50 mV. (A) Representative trace recordings for GluA2/3, showing the effect of medium chain fatty acids decanoic acid (DA), octanoic acid (OA) and VPA (all at 1 mM) and the AMPA receptor inhibitor CNQX (30 \( \mu M \)) on inward currents; and (B) summary of mean normalized currents (±SEM). (C) Representative current traces of inhibitory dose-response curves for octanoic or decanoic acid. (D) Mean inhibitory dose-response curves for octanoic or decanoic acid, graphs show means ± SEM. (E) Representative trace recordings for GluA1, showing the effect of medium chain fatty acids and VPA on inward currents. (F) Summary of mean normalized currents (±SEM). Statistical analysis was performed using ANOVA with Dunnett’s post hoc test. *\( P < 0.05 \), **\( P < 0.001 \), compared to control; +++\( P < 0.001 \), compared to solvent only (DMSO). Scale bars = 15 nA for octanoic acid and 5 nA for decanoic acid.
GYKI 52466 (50 μM) completely blocked *in vitro* epileptiform activity induced by pentylenetetrazol (Fig. 4), indicating that the AMPA receptor antagonism of decanoic acid is sufficient to explain its pharmacological effect *in vitro*.

We have previously observed that chemical modification of medium chain fatty acids can increase their potency against multiple *in vitro* and *in vivo* seizure models (Chang et al., 2012, 2013, 2014a). For example, although octanoic acid shows little seizure control in these models, a branched derivative, 4-methyloctanoic acid is strongly active. We therefore examined the potency of 4-methyloctanoic acid for inhibitory activity at AMPA receptors (GluA2/3) (Fig. 5). This compound showed strong inhibitory activity [IC50 0.84 ± 0.04 mM (n = 14)], consistent with that shown for seizure control. These data are consistent with medium chain fatty acid derivatives providing direct AMPA receptor inhibition relating to seizure control.

**Decanoic acid inhibition of AMPA receptor activity is subunit dependent, non-competitive and voltage dependent**

We next explored the subunit-dependency of decanoic acid inhibition on AMPA receptors. We employed oocytes expressing a homomeric (GluA1 subunit), and heteromeric (GluA1/2 and GluA2/3) AMPA receptors and measured currents following glutamate treatment (100 μM). Similar to the previous experiments, decanoic acid had a potent inhibitory effect on homomeric GluA1 AMPA receptors (Fig. 6A and B; IC50 = 2.09 mM; P < 0.001 compared to solvent only), whereas octanoic acid and valproic acid had no effect. Decanoic acid's potency was greater at the GluA1/2 heteromeric complex (Fig. 6A and B; IC50 = 1.16 mM; P < 0.001 compared to GluA1 homomer), and even greater at the GluA2/3 heteromeric complex (Fig. 6A and B; IC50 = 0.52 mM; P < 0.001 compared to GluA1/2 heteromer). This suggests that decanoic acid is a broad spectrum AMPA receptor inhibitor, but with differing potency at specific subunit combinations.

We further investigated the nature of decanoic acid-dependent AMPA receptor inhibition. We measured glutamate dose-response curves in the absence and presence of either 0.3 mM or 1 mM decanoic acid using GluA2/3 (Fig. 6C and D). Competitive inhibition would be predicted to shift the dose-response curves to the right (increasing the EC50 but with the same maximal response). However, in contrast, we observed a significant reduction in mean EC50s for glutamate in the presence of decanoic acid compared to control [from 0.029 mM for control to 0.015 mM and 0.018 mM for 0.3 mM (P < 0.001) and 1.0 mM (P < 0.01)]

**Figure 4** The effect of AMPA receptor antagonism with GYKI 52466 on epileptiform activity. Epileptiform activity induced by application of pentylenetetrazol (2 mM, K + 6 mM) was monitored following treatment with the selective AMPA receptor antagonist GYKI 52466 at a concentration (50 μM) that results in approximately the same (~60–70%) decrease in AMPA receptor responses (± SD) as is observed with 1 mM decanoic acid (n = 4).

**Figure 5** The effect of 4-ethylloctanoic acid on AMPA (GluA2/A3) mediated current in *Xenopus* oocytes induced by L-glutamate. (A) Representative trace recording showing the effect of 4-ethylloctanoic acid at indicated concentrations on AMPA (GluA2/A3) current following application of glutamate (100 μM). (B) Inhibitory dose-response curves of 4-ethylloctanoic acid (n = 4) in the presence of glutamate (100 μM), with data present as means ± SEM. The responses are normalized to the maximal current response induced by application of L-glutamate for each recording.
Figure 6  Characterization of decanoic acid-dependent AMPA receptor inhibition. In these experiments, *Xenopus* oocytes were used to express various AMPA receptor combinations, and glutamate-elicited currents were measured in the presence of varying decanoic acid concentrations. (A) Representative current trace showing different AMPA receptor subunit combinations (GluA1; GluA1/2; GluA2/3) following exposure to varying decanoic acid concentrations (0.001, 0.05, 0.3, 0.7, 1 and 3 mM) on current following application of glutamate (at 100 μM). Scale bars = 200 nA for GluA1 and GluA1/2; 20 nA for GluA2/3, and (B) mean inhibitory dose-response curves of decanoic acid from different AMPA receptor combinations (inset provides IC50 values) (n = 12). (C) Representative traces from electrophysiological recordings showing the effect of glutamate (0.001, 0.003, 0.01, 0.03, 0.1, 0.3 mM) on GluA2/3 currents in the presence of decanoic acid (at 0.3 mM or 1 mM). Scale bar = 5nA (no decanoic acid); 2 nA (0.3 mM decanoic acid); and 4 nA (1.0 mM decanoic acid). (D) Quantitative evaluation of decanoic acid potency against GluA2/3 currents showing mean glutamate concentration-response curves (n = 5 for each treatment) where responses are normalized to the maximal current for each recording in the absence of decanoic acid. (E) Representative current trace of the inhibitory dose-response curves for decanoic acid in the presence of glutamate (100 μM; n = 20 and 1 mM; n = 6) for GluA2/3 receptors and (F) mean inhibitory dose-response curves for decanoic acid against GluA2/3 in the presence of 100 μM or 1 mM glutamate show little change, suggesting a non-competitive inhibition of AMPA mediated current with respect to glutamate. (G) Representative current traces of the voltage dependence of decanoic acid inhibitory activity, where inhibition curves for decanoic acid in the present of glutamate (100 μM) for GluA2/3 receptors with voltage clamped to −80 and −40 mV. Scale bars = 200 nA and 20 nA, respectively. (H) Mean inhibitory dose-response curves at −80 and −40 mV (inset provides IC50 values) (n = 6).
Decanoic acid, respectively; Fig. 6D] and also a marked reduction in the maximal response at increasing decanoic acid concentrations. Such observations indicate that decanoic acid displays non-competitive inhibition at AMPA receptors. Furthermore, we also compared the mean IC50s of decanoic acid in the presence of low (100 μM) and high (1 mM) glutamate concentrations (Fig. 6E and F). Application of decanoic acid resulted in a concentration-dependent reduction in the glutamate-induced (100 μM) AMPA receptor current with an IC50 value of 0.52 ± 0.02 mM (n = 12; Fig. 6E and F). Repeating these experiments at higher glutamate concentrations (1 mM) did not alter the inhibitory effect (0.54 ± 0.03 mM, n = 10; Fig. 6E and F), suggesting that decanoic acid inhibition is not reversed by higher glutamate concentrations and is acting as a non-competitive inhibitor of AMPA receptors. This indicates that decanoic acid is likely to bind to a different region of AMPA receptors from that to which glutamate binds, and that this inhibitory mechanism may be shared amongst a number of fatty acids with anti-seizure activity.

We then investigated the voltage-dependence of direct AMPA receptor inhibition by decanoic acid using GluA2/3. Here, we clamped the voltage across the oocyte membrane at different membrane potentials, and examined changes in inhibitory activity of decanoic acid on AMPA-dependent current that may occur during synaptic depolarization. In these experiments, decanoic acid shows enhanced AMPA inhibition at the more depolarized membrane potential, −40 mV, where the IC50 is 0.43 ± 0.09 mM (n = 6) in comparison to −80 mV, where the IC50 is 1.11 ± 0.05 mM (n = 6) (Fig. 6G and H).

**Decanoic acid binds in the channel of AMPA receptors**

We next sought to identify a potential binding site for decanoic acid within the AMPA receptor using a modelling approach with the AMPA-sensitive, homotetrameric, rat GluA2 receptor (3KG2). *In silico* analysis was used to evaluate the binding of both decanoic acid and perampanel in the transmembrane domain of 3KG2 (Morris et al., 2009), where over 2.5 million confirmations of decanoic acid and 3KG2 were evaluated, and the 25 conformations producing the lowest binding energy were used to define specific binding locations within the receptor. From these, the frequency of individual amino acid residues participating in binding (i.e. within 6 Å of decanoic acid) were determined (Supplementary Fig. 3). The most frequent residues involved in binding decanoic acid span residues 584–590 (Fig. 7A and B) (Supplementary Fig. 3). This coincides with the M3 helix of the transmembrane domain and, specifically, those residues found to influence the inward current through the receptor and thought to be involved in gating. We also examined the site for perampanel, a recently introduced treatment for partial onset seizures and showing efficacy in drug resistant epilepsy (Russo et al., 2012; Rektor, 2013). Our modelling approach predicted perampanel to bind to a region in the border between S1 and the channel, consistent with that identified in other reports (Szenasi et al., 2008; Rogawski, 2011). These data suggest that decanoic acid binds directly to the AMPA receptor channel, at a location separate from that of perampanel, and thus may exhibit a different physiological effect to perampanel.
Discussion

The predominant mechanism of ketogenic diets, as the name suggests, has been widely considered to be through the production of ketone bodies (Bough and Rho, 2007; Rho and Stafstrom, 2011), such as 3-hydroxybutyrate and acetoacetate, since these are found to be elevated in the plasma of patients on the diet (Huttenlocher, 1976). However, a correlation between blood ketone levels and seizure control in patients and animal models has not been consistently found (Thavendiranathan et al., 2000). Our study suggests that decanoic acid, rather than ketones, may provide the direct molecular mechanism of MCT ketogenic diet, in two ex vivo models for drug-resistant epilepsy, although ketones are likely to provide other benefits (Bough and Rho, 2007; Rho and Sankar 2008; Rho and Stafstrom, 2011; Kim et al., 2015). This is further supported by other studies showing that ketone bodies do not directly alter excitatory or inhibitory hippocampal synaptic transmission (Thio et al., 2000) nor affect epileptiform activity (either interictal or ictal activity) induced by 4-aminopyridine in hippocampal-entorhinal cortex slices (Thio et al., 2000), although ketones have been shown to modulate vesicular glutamate transporter activity at pre-synaptic sites (Juge et al., 2010). Nevertheless, there may be circumstances, when ketones do play a greater role such as in Glut1 deficiency, in which ketones from the ketogenic diet provide the brain with an alternative energy source (Veggiotti and De Giorgis, 2014). Moreover, the ketogenic diet in the longer term may modify metabolic and gene expression, which could have important disease-modifying effects (Masino et al., 2011; Kim et al., 2015). Also, the ketogenic diet (with reduced glucose) decreases cellular pyruvate/oxaloacetate concentrations, which has recently been shown to hyperpolarize neurons through an effect on neuronal potassium currents (Sada et al., 2015).

The classical (long chain triglyceride; LCT) ketogenic diet, which has been shown to be as effective as the MCT diet (Neal et al., 2009), provides up to 90% of the calories in the diet as fat and is extremely restrictive. In contrast, the MCT diet allows less energy to be provided as total fat (typically resulting in a total fat intake of 65–75% energy) allowing for a less restrictive and more varied diet. The implication of our results for the mechanism of action for the classical diet are yet to be explored; however, long chain fats are metabolized to shorter chain fats and it would thus be expected that serum medium chain fats will be increased. Future studies to monitor brain medium fatty acid levels in animal models and in patient plasma during ketogenic diets will be necessary to determine the role of fatty acids in the control of seizures.

Decanoic acid is a major constituent of the MCT ketogenic diet, providing ~40% of the medium chain fat within the diet (Sills et al., 1986a). Even though decanoic acid is extensively metabolized to carbon dioxide, ketone bodies, and long chain fatty acids, it has been reported that there are high concentrations of decanoic acid (averaging 156.7 μM) in the serum of children with intractable epilepsy treated with MCT diet for the control of drug-resistant seizures (Haidukewych et al., 1982; Sills et al., 1986a; Dean et al., 1989). A direct correlation between decanoic acid concentrations and seizure control has not, however, been shown, partly because the studies are too small to demonstrate such a correlation, but also because the ketogenic diet may have multiple other actions. Importantly, mice treated with decanoic acid by gastric gavage (30 mmol/kg; Wlaz et al., 2012) have increased brain decanoic acid concentrations (up to 240 μM), which represent 60–80% of serum levels. These results indicate that fatty acids are present in appreciable amounts in the peripheral blood and brain and therefore are ideally placed to have an effect on seizure control in the brain. Decanoic acid has also been shown to delay the onset of picrotoxin-induced clonic seizures and prolong the survival time in mice with pentylentetrazol-induced convulsions (Nakamura et al., 1990). In addition, there is a direct effect of the fatty acids contained in MCT on cerebral excitability (Huttenlocher et al., 1971; Sills et al., 1986a, b). As we also show that decanoic acid inhibits epileptiform activity in vitro, it is likely that decanoic acid is a significant therapeutic component of the diet.

We determined the acute effect of decanoic acid on synaptic transmission in the CA1 area of the rat hippocampus and identified that decanoic acid reduced EPSC amplitude, at a similar concentration to peak plasma concentrations in children undergoing the diet (300 μM; Haidukewych et al., 1982; Sills et al., 1986a; Dean et al., 1989) and in a manner consistent with a postsynaptic effect. Moreover, the same concentration of decanoic acid had no appreciable effect on inhibitory transmission. These data indicate that decanoic acid acts at AMPA receptors. These receptors provide a recognized target for seizure control, and mediate fast glutamatergic synaptic transmission in the CNS (Traynelis et al., 2010; Rogawski, 2011). AMPA receptors play a key role in generating and propagating epileptic activity and, in the long-term, adaptive cellular plasticity associated with epileptogenesis (Rogawski and Donevan, 1999; Chapman, 2000). The receptors are present in all areas of the brain relevant to epilepsy, including the cerebral cortex, amygdala, thalamus and hippocampus (Beneyto and Meador-Woodruff, 2004; Rogawski, 2011). Furthermore, AMPA receptor antagonists have a broad spectrum of anticonvulsant activity in various in vitro and in vivo epilepsy models (Rogawski and Donevan, 1999; Rogawski, 2011). Here we show that the degree of AMPA receptor antagonism by decanoic acid is sufficient to explain its antiseizure effect. Similarly, perampanel, a recently approved treatment for refractory partial epilepsy, acts through AMPA receptor antagonism (Rektor, 2013). Thus, our results showing that decanoic acid reduces the magnitude of fast glutamatergic signalling in the hippocampus are consistent with previous reports that AMPA receptors are a recognized target for antiseizure therapies.
Decanoic acid: an AMPA receptor antagonist

(Meldrum and Rogawski, 2007; Szenasi et al., 2008; Russo et al., 2012).

The results from ex vivo hippocampal slices do not, however, distinguish a direct from an indirect effect of decanoic acid on AMPA receptors. To overcome this, we used a heterologous expression model, where AMPA receptors were expressed in Xenopus oocytes to enable a detailed characterization of the effect of decanoic acid on AMPA receptor activity. Decanoic acid directly inhibited AMPA receptors comprised of GluA1 homodimers, and GluA1/2 and GluA2/3 heterodimers—the latter two represent the two most abundant AMPA receptor combinations in the adult brain (Santos et al., 2009; Wang et al., 2012). It is interesting to note that patients with chronic epilepsy show a significant increase of hippocampal dendritic GluA2/3 subunits in dentate granule cells (de Lanerolle et al., 1989), and our data would suggest a concomitant enhanced efficacy of decanoic acid in this population. GluA subunits show differential spatial and temporal changes in subunit expression throughout development (Talos et al., 2006), and the GluA2/3 subunits are expressed at increased levels during postnatal development (postnatal Days 10–15) in the rat hippocampus (Arai et al., 1997), and long-term expression changes following the development of epilepsy in animal models (Friedman et al., 1994). These results indicate that decanoic acid exerts a direct effect on AMPA-mediated currents, at concentrations as low as 100 μM (providing ~20% inhibition), suggesting a likely influence on neuronal function in patients on the MCT ketogenic diet. However, the finding that decanoic acid likely has additional therapeutic targets due to its effect on phosphoinositides (Chang et al., 2012, 2014a, b), raises the question of whether this degree of AMPA receptor antagonism is sufficient to explain its therapeutic effects in humans. Perampanel, a selective AMPA receptor antagonist, at the free concentrations observed to be efficacious in humans, 30–50 nM (Rogawski and Hanada, 2013), results in ~20% reduction in field EPSP slope (Ceolin et al., 2012). This effect is of a similar magnitude to the effect that we observed with therapeutically relevant concentrations of decanoic acid, indicating that the AMPA receptor antagonism may be sufficient to explain the antiseizure effects in humans (although we cannot exclude that its' effect on other targets could also play a part).

We continued our investigation into AMPA receptor inhibition by further characterizing the mechanism of decanoic acid inhibition, in particular determining whether it competes with glutamate for binding to the AMPA receptor. This is relevant as during conditions in which there are large rises in glutamate concentrations (such as seizure activity), competitive inhibitors may be less effective. However, we clearly demonstrate that varying the glutamate concentration by an order of magnitude does not alter the IC50 of decanoic acid inhibition, indicating that decanoic acid is a non-competitive inhibitor at AMPA receptors. The potency of decanoic acid-dependent AMPA receptor inhibition is therefore independent of increased glutamate during seizure activity and will still occur at synaptic glutamate concentrations in the millimolar range (Clements et al., 1992). We also determined that AMPA receptor inhibition by decanoic acid is voltage-dependent, and is more effective at depolarized potentials. This voltage dependence suggests that the therapeutic effect of decanoic acid in reducing AMPA receptor currents is enhanced during post-synaptic activation and seizure propagation. This result also suggests that the binding site for decanoic acid lies in or near to the channel region of the receptor and is consistent with the properties of known AMPA receptor pore blockers such as the polyamines (Washburn and Dingledine, 1996).

Our modelling of the binding of decanoic acid to AMPA receptors also suggests a binding site in the channel region of the receptor. Our data indicate that decanoic acid binds by means of hydrogen bonding between its two carboxylic acid oxygens and the two hydrogens of the cyclic amine group of proline at residue position 584 on each of the four M3 helices subunits within the ion channel. It is likely that the binding of decanoic acid to each of the four subunits cooperatively contributes to its therapeutic effects. We believe that this mode of action will provide both steric effects restricting the physical dimensions of the ion channel pore coupled to electrostatic interactions between the negatively charged carboxylic group and cations flowing through the ion channel. Interactions between decanoic acid and cations passing through the channel would not only result in further narrowing the ion channel pore, but also create a positive electrostatic field which may serve to repel and prevent additional cations from passing through the blocked ion channel. However, the precise mechanistic aspects of decanoic acid function, including possible effect on receptor desensitization, remain unclear. The distinct localization of binding for decanoic acid and perampanel (Szenasi et al., 2008; Rogawski, 2011) suggests different inhibitory profiles and, possibly, clinical effects. This may explain why certain adverse effects of perampanel, such as increased aggression (Rugg-Gunn, 2014; Steinhoff et al., 2014), are not so evident with the MCT ketogenic diet. Moreover, as perampanel and decanoic acid act at separate sites, it is possible that they have a cooperative effect at the AMPA receptor, suggesting that perampanel and the ketogenic diet could be synergistic.

Our results have far-reaching clinical implications. For Lennox-Gastaut syndrome, Doose syndrome and Dravet’s syndrome antiepileptic drugs are often insufficient to obtain seizure control and non-pharmacological interventions are often required. Here the MCT diet can be effective in seizure management (Kossoff and Rho, 2009; Vanstraten and Ng, 2012; Laux and Blackford, 2013), and enhanced dietary intake of decanoic acid may provide additional therapeutic benefit. Furthermore, treatment of adults with drug-resistant epilepsy, who show poor compliance to the stringent dietary regimen necessary for the MCT diet, may better tolerate a normal diet with just added decanoic acid, e.g. in the form of a triglyceride.
There are a range of limitations to the discovery of an acute effect of decanoic acid on seizure control. First, it is likely that decanoic acid also has chronic effects, as has been shown recently on mitochondrial proliferation (Hughes et al., 2014), and these effects may also have roles in decanoic acid’s therapeutic function. In addition, the role of metabolism on elevated blood levels of decanoic acid (Rho and Sankar, 2008; Rho and Stafstrom, 2011) remains unclear. Is a reduction in carbohydrate load necessary for elevated blood decanoic acid levels? Recent studies have suggested that dietary MCT oil, concomitant with a non-restricted carbohydrate diet, gave rise to ketosis (Courchesne-Loyer et al., 2013), although changes in specific medium chain fatty acids in the plasma were not determined. Future studies monitoring decanoic acid in the plasma of patients or healthy individuals on different composition MCT oils, or with differing carbohydrate intakes, should provide indications of the dietary conditions necessary to elevate plasma decanoic acid levels to provide seizure protection through direct AMPA receptor inhibition.

The direct effect of decanoic acid on AMPA receptor-mediated currents raises a concern of a detrimental effect on cognitive function. Numerous studies have demonstrated that AMPA receptors contribute to synaptic strengthening during long-term potentiation, a cellular model of synaptic plasticity, and experience-dependent neuronal plasticity (Sanderson et al., 2008). However, neither competitive nor non-competitive antagonists of AMPA receptors (at concentrations that inhibit seizure activity) had an effect on long-term potentiation (a cellular correlate of learning and memory) (Sanderson et al., 2008), and this is consistent with in vivo data in which AMPA receptor antagonists at therapeutic doses do not affect cognition (Pan et al., 2010). Indeed, in humans, the MCT ketogenic diet has been shown to have diverse positive effects on brain function, such as increased alertness, better cognitive functioning, and improved behaviour, not only in epilepsy patients (Kinsman et al., 1992; Pulsifer et al., 2001) but also in patients with type 1 diabetes given an insulin infusion (Page et al., 2009). The extent to which these effects can be attributed to decanoic acid or other components of the diet remains to be determined.

**Funding**

We gratefully acknowledge an NC3Rs grant G0900775 to R.S.B.W. and M.W. to support this research, and PhD studentship to K.A. by Vitallo Ltd. P.E.C. is grateful for funding from the Royal Society. Part of this work was undertaken at UCLH/UCL which receives a proportion of funding from the Department of Health’s NIHR Biomedical Research Centers funding scheme.

**Supplementary material**

Supplementary material is available at *Brain* online.

**References**

Arai AC. GYKI 52466 has positive modulatory effects on AMPA receptors. Brain Res 2001; 892: 396–400.

Arai Y, Mizuguchi M, Takashima S. Developmental changes of glutamate receptors in the rat cerebral cortex and hippocampus. Anat Embryol (Berl) 1997; 195: 65–70.

Beneyto M, Meador-Woodruff JH. Expression of transcripts encoding AMPA receptor subunits and associated postsynaptic proteins in the macaque brain. J Comp Neurol 2004; 468: 530–54.

Bough KJ, Rho JM. Anticonvulsant mechanisms of the ketogenic diet. Epilepsia 2007; 48: 43–58.

Ceolin L, Bortolotto ZA, Bannister N, Collingridge GL, Lodge D, Volanskins A. A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampus. Neurochem Int 2012; 61: 517–22.

Chang P, Orabi B, Deranleau RM, Dharm M, Hoeller O, Shimshoni JA, et al. The antiepileptic drug valproic acid and other medium-chain fatty acids acutely reduce phosphoinositide levels independently of inositol in Dictyostelium. Dis Model Mech 2012; 5: 115–24.

Chang P, Terbach N, Plant N, Chen PE, Walker MC, Williams RS. Seizure control by ketogenic diet-associated medium chain fatty acids. Neuropharmacology 2013; 69: 105–14.

Chang P, Walker MC, Williams RS. Seizure-induced reduction in PIP3 levels contributes to seizure-activity and is rescued by valproic acid. Neurobiol Dis 2014a; 62: 296–306.

Chang P, Zuckermann A, Williams S, Close AJ, Cano-Jaime M, McEvoy JP, et al. Seizure control by derivatives of medium chain fatty acids associated with the ketogenic diet show novel branching-point structure for enhanced potency. J Pharmacol Exp Ther 2014b; 352: 43–52.

Chapman AG. Glutamate and epilepsy. J Nutr 2000; 130: 1043S–5S.

Clements JD, Lester RA, Tong G, Jahir CE, Westbrook GL. The time course of glutamate in the synaptic cleft. Science 1992; 258: 1498–501.

Courchesne-Loyer A, Fortier M, Tremblay-Mercier J, Chouinard-Watkins R, Roy M, Nugent S, et al. Stimulation of mild, sustained ketonemia by medium-chain triacylglycerols in healthy humans: estimated potential contribution to brain energy metabolism. Nutrition 2013; 29: 635–40.

de Lanerolle NC, Kim JH, Robbins RJ, Spencer DD. Hippocampal interneuron loss and plasticity in human temporal lobe epilepsy. Brain Res 1989; 495: 387–95.

Dean HG, Bonser JC, Gent JP. HPLC analysis of brain and plasma for octanoic and decanoic acids. Clin Chem 1989; 35: 1945–8.

Friedman LK, Pellegrini-Giampietro DE, Sperber EF, Bennett MV, Moshe SL, Zukin RS. Kainate-induced status epilepticus alters glutamate and GABA receptor gene expression in adult rat hippocampus: an in situ hybridization study. J Neurosci 1994; 14: 2697–707.

Haddukewych D, Forsythe WI, Sils M. Monitoring octanoic and decanoic acids in plasma from children with intractable epilepsy treated with medium-chain triglyceride diet. Clin Chem 1982; 28: 642–5.

Hughes SD, Kanabus M, Anderson G, Hargreaves IP, Rutherford T, O'Donnell M, et al. The ketogenic diet component decanoic acid increases mitochondrial citrate synthase and complex I activity in neuronal cells. J Neurochem 2014; 129: 426–33.

Huttenlocher PR. Ketonemia and seizures: metabolic and anticonvulsant effects of two ketogenic diets in childhood epilepsy. Pediatr Res 1976; 10: 536–40.
Huttenlocher PR, Wilbourn AJ, Signore JM. Medium-chain triglycerides as a therapy for intractable childhood epilepsy. Neurology 1971; 21: 1097–103.

Juge N, Gray JA, Omote H, Miyaji T, Inoue T, Hara C, et al. Metabolic control of vesicular glutamate transport and release. Neuron 2010; 68: 99–112.

Kim DY, Simeone KA, Simeone TA, Pandya JD, Wilke JC, Ahn Y, et al. Ketone bodies mediate anti-seizure effects through mitochondrial permeability transition. Ann Neurol 2015; 78: 77–87.

Kinsman SL, Vining EP, Quaskey SA, Mellitis D, Freeman JM. Efficacy of the ketogenic diet for intractable seizure disorders: review of 58 cases. Epilepsia 1992; 33: 1132–6.

Kossoff EH, Rho JM. Ketogenic diets: evidence for short- and long-term efficacy. Neurotherapeutics 2009; 6: 406–14.

Laux L, Blackford R. The ketogenic diet in Dravet syndrome. J Child Neurol 2013; 28: 1041–4.

Levy RG, Cooper PN, Giri P. Ketogenic diet and other dietary treatments for epilepsy. Cochrane Database Syst Rev 2012; 3: CD001903.

Likhodi SS, Musa K, Mendonca A, Dell C, Burnham WM, Cunnane SC. Dietary fat, ketosis, and seizure resistance in rats on the ketogenic diet. Epilepsia 2008; 41: 1400–10.

Liu YM. Medium-chain triglyceride (MCT) ketogenic therapy. Epilepsia 2008; 49 Suppl 8: 33–6.

Masino SA, Li T, Theofils P, Sandau US, Ruskin DN, Fredholm BB, et al. A ketogenic diet suppresses seizures in mice through adenosine A1 receptors. J Clin Invest 2011; 121: 2679–83.

Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development. Neurotherapeutics 2007; 4: 18–61.

Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem 2009; 30: 2785–91.

Nakamura J, Miwa T, Sasaki H, Shibasaki J, Kaneto H. Effect of straight chain fatty acids on seizures induced by picrotoxin and pentyleneetrazole in mice. J Pharmacobiodyn 1990; 13: 76–81.

Neal EG, Chaffe H, Schwartz RH, Lawson MS, Edwards N, Giri P. Ketogenic diet and other dietary treatments for epilepsy. Cochrane Database Syst Rev 2012; 3: CD001903.

Oldendorf WH. Carrier-mediated blood-brain barrier transport of short-chain monoenaturated organic acids. Am J Physiol 1973; 224: 1450–3.

Page KA, Williamson A, Yu N, McNay EC, Dzurja J, McCormrin BJ, et al. Medium-chain fatty acids improve cognitive function in intensively treated type 1 diabetic patients and support in vitro synaptic transmission during acute hypoglycemia. Diabetes 2009; 58: 1237–44.

Pan Y, Larson B, Araujo JA, Lau W, de Rivera C, Santana R, et al. Dietary supplementation with medium-chain TAG has long-lasting cognition-enhancing effects in aged dogs. Br J Nutr 2010; 103: 1746–54.

Pulsifer MB, Gordon JM, Brandt J, Vining EP, Freeman JM. Effects of ketogenic diet on development and behavior: preliminary report of a prospective study. Dev Med Child Neurol 2001; 43: 301–6.

Rector I. Perampanel, a novel, non-competitive, selective AMPA receptor antagonist as adjunctive therapy for treatment-resistant partial-onset seizures. Expert Opin Pharmacother 2013; 14: 225–33.

Rho JM, Sankar R. The ketogenic diet in a pill: is this possible? Epilepsia 2008; 49 (Suppl 8): 127–33.

Rho JM, Stafstrom CE. The ketogenic diet: What has science taught us? Epilepsy Res 2011; 100: 203–346.

Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr 2011; 11: 56–63.

Rogawski MA, Donevan SD. AMPA receptors in epilepsy and as targets for antiepileptic drugs. Adv Neurol 1999; 79: 947–63.

Rogawski MA, Hanada T. Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. Acta Neurol Scand Suppl 2013; 19–24.

Rugg-Gunn F. Adverse effects and safety profile of perampanel: a review of pooled data. Epilepsia 2014; 55 (Suppl 1): 13–15.

Russo E, Gitto R, Citarro R, Chimirri A, De SG. New AMPA antagonists in epilepsy. Expert Opin Investig Drugs 2012; 21: 1371–89.

Sada N, Lee S, Katsu T, Otsuki T, Inoue T. Epilepsy treatment. Targeting LDH enzymes with a stiripentol analog to treat epilepsy. Science 2015; 347: 1362–7.

Sanderson DJ, Good MA, Seeburg PH, Sprengel R, Rawlins JN, Banerman DM. The role of the GluR-A (GluR1) AMPA receptor subunit in learning and memory. Prog Brain Res 2008; 169: 159–78.

Santos SD, Carvalho AL, Caldeira MV, Duarte CB. Regulation of AMPA receptors and synaptic plasticity. Neuroscience 2009; 158: 105–25.

Sills MA, Forsythe WI, Haidukewych D. Role of octanoic and decanoic acids in the control of seizures. Arch Dis Child 1986a; 61: 1173–7.

Sills MA, Forsythe WI, Haidukewych D, MacDonald A, Robinson M. The medium chain triglyceride diet and intractable epilepsy. Arch Dis Child 1986b; 61: 1168–72.

Steinhoff BJ, Hamer H, Trinka E, Schulze-Bonhage A, Bien C, Mayer T, et al. A multicenter study of clinical experiences with perampanel in real life in Germany and Austria. Epilepsia Res 2014; 108: 986–8.

Szenasi G, Végh M, Szabó G, Kertesz S, Kapus G, Albert M, et al. A ketogenic diet suppresses seizures in mice through adenosine A1 receptors. J Clin Invest 2011; 121: 2679–83.

Thavendiranathan P, Mendonca A, Dell C, Likhodi SS, Musa K, Iracleres C, et al. The MCT ketogenic diet: effects on animal seizure models. Exp Neurol 2000; 161: 696–703.

Thio LL, Wong M, Yamada KA. Ketone bodies do not directly alter excitatory or inhibitory hippocampal synaptic transmission. Neurology 2000; 54: 324–31.

Traynelis SF, Wollin LH, McGinn BJ, Menini FS, Vance KM, Ogden KK, et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev 2010; 62: 405–96.

Vanstraten AF, Ng YT. Update on the management of Lennox–Gastaut syndrome. Pediatr Neurol 2012; 47: 153–61.

Veggiotti P, De Giorgis, V. Dietary treatments and new therapeutic perspectives in GLUT1 deficiency syndrome. Curr Treat Options Neurol 2014; 16: 291.

Wang G, Gilbert J, Man HY. AMPA receptor trafficking in homeostatic synaptic plasticity: functional molecules and signaling cascades. Neural Plast 2012; 2012: 825364.

Washburn MS, Dingleline R. Block of alpha-amino-3-hydroxy-5-methyl-4-oxazolonic acid receptor subunit expression in forebrain and relationship to regional susceptibility to hypoxic/ischemic injury. II. Human cerebral white matter and cortex. J Comp Neurol 2006; 497: 61–77.

Wlaz P, Socala K, Nieoczym D, Z, et al. Metabolic control of seizures. Arch Dis Child 1986a; 61: 1173–7.

Wlaz P, Socala K, Nieoczym D, Z, et al. Metabolic control of seizures. Arch Dis Child 1986b; 61: 1168–72.

Xu X, Muller-Taubenberger A, Adley KE, Pavolleck N, Lee VW, Wiedemann C, et al. Attenuation of phospholipid signaling provides a novel mechanism for the action of valproic acid. Eukaryot Cell 2007; 6: 899–906.